ABCB1 and brain neoplasm: Future studies should focus on the development of a two-pronged chemotherapeutic approach, targeting CD133 and MDR1 as a means to eradicate CD133 positive drug resistant cells and ultimately improve treatment outcomes for patients with brain tumors, including recurrent PAs.